The number of companies choosing to stay private for longer continues to grow and asset allocators are supporting this trend with global private markets AUM now at circa USD 24 trillion. And the US is leading the way in this trend. Private growth fundraising continues to rise in the US whilst it may be slowing in Europe and other parts of the world.
"FlowwCapital is therefore excited to share more about the first US opportunities from key sectors, made available to US and non-US investor through different regulatory journeys."
Built to be hard to copy
Bringing US private companies to a breadth of investors isn't a listing-page problem. It's three things that rarely coexist: the regulatory permissions, the cross-border infrastructure to settle and service securities, and the compliance discipline once live. Most platforms have built one aspect. Floww built all three.
Here's the practical effect. Until now, an investor outside the US wanting exposure to US private company growth financing had two options: go direct and absorb the cross-border regulatory risk themselves, or go through a platform that wasn't built to carry that risk on their behalf. We are closing that gap — the access exists, it's compliant end to end, and it's live.
What's live today
Our first three US deals are companies operating in the AI and biotech space. They're open to our investor community today through our US and UK channels.
Eos SENOLYTIX, Inc. A biotechnology company developing therapeutics that target the biology of aging itself, not just its symptoms. Its lead candidate, PTC-2105, is a mitochondrial-targeted molecule built to recharge aging cells while clearing the senescent "zombie" cells behind age-related decline, sitting on a platform backed by roughly eight years of research. Its first target is sarcopenia and sarcopenic obesity: the age-related muscle loss that today's GLP-1 weight-loss drugs cause but don't treat, a large and growing population with no approved therapy.
Oral Biolife. A US oral health biotech company developing a hydrogel platform that treats periodontal (gum) disease by regenerating lost bone and tissue, using mechanical stress to trigger the body's own repair signals, without surgery or grafting.
New Sapience. A Maryland-based AI company built around a different bet on Artificial Intelligence: instead of scaling data and compute, it teaches machines to reason from human-derived knowledge, building what it calls an "inner world model".
Find out more here:
Your support
If you are already in our network, log in and find out more about the companies. If you are interested in US dealflow and haven't joined yet, register your interest and gain access to the latest deals on confirmation of your investor status.
Important, capital at risk: This content is a financial promotion about specific investment opportunities on FlowwCapital: Eos SENOLYTIX, Oral Biolife and New Sapience. Investing in early-stage private companies involves a high degree of risk, including the risk of total loss of capital. Investments are illiquid: you may not be able to sell them when you want to. Past performance of other investments is not a reliable indicator of these investments' performance. FlowwCapital does not provide investment advice.
UK / international: This promotion has been approved by Floww Markets UK Ltd (FRN: 980098), authorised and regulated by the Financial Conduct Authority. Access to these opportunities from outside the United States is offered under Regulation S of the US Securities Act and is restricted to sophisticated investors and high net worth individuals. Not suitable for retail investors.
US: Each of these three companies has a Rule 506(c) offering under Regulation D of the US Securities Act. This communication is directed solely at accredited investors as defined under Rule 501 of Regulation D. FlowwCapital and the issuers are required to take reasonable steps to verify accredited investor status before accepting any investment: self-certification alone does not satisfy this requirement. This does not constitute an offer to sell, or a solicitation to buy, any security.